

**FAX TRANSMITTAL  
TO THE UNITED STATES PATENT OFFICE**

Applicants Docket Number:  
**HMR2041US NP1**

Applicants:  
**Kurt M. Kessler**

Serial No.  
**09/760,590**

Filing Date:  
**January 16, 2001**

Title of Invention:  
**Ethanol Solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-one**

**CERTIFICATE OF TRANSMISSION**

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, at (703) 872-9306, on

Date of Deposit May 7, 2004

Printed Name of Person Signing Certificate Bonnie Stein

Signature Bonnie Stein

**Total Number of Pages Sent: 19**

Attorney: **Lawrence L. Martin**

Group Art Unit: **1625**

Examiner: **Celia C. Chang**

TO: Mail Stop AF  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Please acknowledge receipt of the below-listed documents for the above Application by returning this sheet, signed and dated, by return telefax to (908) 231-2626. If any fees are required, please charge our deposit account (18-1982) in the name of Aventis Pharmaceuticals Inc.

☒ **Amendment Pursuant to 37 CFR 1.121(c) and Response Pursuant to 37 C.F.R. 1.116 - 11 pgs.**

☐ **Fee Transmittal**

☐ **Charge deposit account, in duplicate**

☐ **Petition under 37 CFR \_\_\_\_\_**

☐ **Extension of Time Petition - 1 month - 1 pg.**

☒ **Other FAX Transmittal for Certificate of Correction dated April 28, 2004 - 1 pg. and Request for Certificate of Correction Under 35 U.S.C. 154/155 and 37 C.F.R. 1.322/323 faxed April 28, 2004 - 3 pgs.**

☐ **Issue Fee Transmittal & Advance Order**

☒ **Other Executed Declaration Under Rule 132 - 3 pgs.**

☐ **Maintenance Fee Transmittal**

☐ **Other**

Receipt Confirmed:

Signed

Dated

Aventis Pharmaceuticals Inc., Route 202-206, P.O. Box 6800, Bridgewater, New Jersey 08807, U.S.A. [www.aventis.com](http://www.aventis.com)  
NOTICE: The documents accompanying this telecopy transmission are intended only for the use of the individual or entity named above. If you have received this telecopy in error, please immediately notify the sender by telephone to arrange for the return of the original documents.

Aventis Pharmaceuticals Inc. template (March 2001)

MAY. 7. 2004 2:00PM

AVENTIS US PAT DEPT

NO. 2530 P. 2

# PATENT

**Docket No.: HMR2041 US NP1**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
Kurt M. Kessler

Examiner: Celia C. Chang

Art Unit: 1625

Serial No.: 09/760,590

Filed: 01/16/01

Title: Ethanol Solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-one

**CERTIFICATE OF TRANSMISSION**  
I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, at (703) 872-9306, on

Date of Deposit: May 7, 2004

Printed Name of Person Signing Certificate: Bonnie Stein

Signature: Bonnie Stein

**AMENDMENT PURSUANT TO 37 C.F.R. § 1.121 (c) AND  
RESPONSE PURSUANT TO 37 C.F.R. § 1.116**

Box AF

Commissioner for Patents

Washington, D.C. 20231

Sir:

This is in response to the outstanding Final Office Action dated February 11, 2004, Paper Number 20, for which a response is due by May 11, 2004, in the above-identified patent application. Applicants respectfully request entry of the following remarks and amendments. Applicants request reconsideration and withdrawal of all outstanding rejections in light of the aforesaid remarks and amendments.